Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C

Gastroenterology. 1993 Mar;104(3):903-5. doi: 10.1016/0016-5085(93)91029-h.

Abstract

A 66-year-old man was treated for chronic active hepatitis C with 3 MU of recombinant interferon alfa-2a three times weekly. Nine months before interferon therapy, a mild lichen planus had been diagnosed, which exacerbated within 4 weeks of treatment to a generalized erosive lichen planus. After 8 weeks, interferon therapy was stopped because local measures did not improve skin lesions. Otherwise, the patient tolerated interferon therapy well, and the initially 20-fold elevated aminotransferase levels returned to normal. Four weeks after discontinuation of interferon therapy, nearly all mucosal and skin lesions had disappeared. But 8 weeks after the discontinuation, aminotransferase levels again rose to 10 times the normal range. Treating physicians should know that a preexisting lichen planus will potentially exacerbate as a side effect of interferon alfa-2a therapy of a chronic hepatitis. However, because this is the first report on this association, further observations are needed to decide the clinical relevance.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Hepatitis C / therapy*
  • Hepatitis, Chronic / therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects*
  • Lichen Planus / pathology*
  • Male
  • Mouth Diseases / pathology
  • Recombinant Proteins

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins